المؤلفون: Winald R. Gerritsen, A.C.M. van den Bergh, Inge M. van Oort, Ronald de Wit, Carin A. Uyl-de Groot, Andre M. Bergman, Malou C.P. Kuppen, Reindert J.A. van Moorselaar, Hans M. Westgeest, Jules Lavalaye, Metin Tascilar, Alfons J.M. van den Eertwegh, Diederik M. Somford, Niven Mehra, Katja K.H. Aben

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Health Technology Assessment (HTA), Medical Oncology, Internal medicine, Medical oncology, CCA - Cancer Treatment and quality of life, Urology

المصدر: Clinical genitourinary cancer, 20(1), 43-52. CIG MEDIA GROUP, LP
Clinical Genitourinary Cancer, 20(1), 43-52. Elsevier
Clinical Genitourinary Cancer, 20, 43-52
Clinical Genitourinary Cancer, 20, 1, pp. 43-52
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Tascilar, M, Mehra, N, Lavalaye, J, Somford, D M, Aben, K K H, Bergman, A M, de Wit, R, van den Bergh, A C M, de Groot, C A U & Gerritsen, W R 2022, ' Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population : Results From the CAPRI-Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 20, no. 1, pp. 43-52 . https://doi.org/10.1016/j.clgc.2021.10.008Test

مصطلحات موضوعية: Male, Bisphophonates, medicine.medical_specialty, Pathologic fracture, Urology, Population, Butylated Hydroxyanisole, Bone Neoplasms, Castration resistant, Skeletal related events, Bone health, Prostate cancer, SDG 3 - Good Health and Well-being, Spinal cord compression, Bone Density, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Medicine, Humans, education, Netherlands, Real-world evidence, education.field_of_study, business.industry, Bone metastases, Life-prolonging drugs, medicine.disease, Prostatic Neoplasms, Castration-Resistant, Denosumab, Oncology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Orthopedic surgery, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27d177b59c6e2b3659b939a21de276f6Test
https://research.rug.nl/en/publications/6aff08ca-2583-4fbf-80f0-7e6b97065874Test

المؤلفون: N.I. Weijl, Carin A. Uyl-de Groot, Lidwine W. Tick, Andre M. Bergman, Winald R. Gerritsen, Daan ten Bokkel Huinink, Hans M. Westgeest, Jules Lavalaye, Katja K.H. Aben, Inge M. van Oort, Fons A.J.M. van den Eertwegh, Malou C.P. Kuppen, Menuhin I. Lampe, Yes A J van de Wouw, Jeroen R.J.A. van Moorselaar, Joan van den Bosch, Juleon L.L.M. Coenen, Rik D.M. Somford, Tineke J. Smilde, Niven Mehra, Mathijs P. Hendriks

المساهمون: Internal medicine, CCA - Cancer biology and immunology, Urology, CCA - Cancer Treatment and quality of life, Health Technology Assessment (HTA)

المصدر: Westgeest, H M, Kuppen, M C P, van den Eertwegh, F A J M, van Oort, I M, Coenen, J L L M, van Moorselaar, J R J A, Aben, K K H, Bergman, A M, Huinink, D T B, van den Bosch, J, Hendriks, M P, Lampe, M I, Lavalaye, J, Mehra, N, Smilde, T J, Somford, R D M, Tick, L, Weijl, N I, van de Wouw, Y A J, Gerritsen, W R & Groot, C A U 2021, ' High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients : Results from the Dutch CAPRI-Registry ', Journal of Palliative Medicine, vol. 24, no. 12, pp. 1789-1797 . https://doi.org/10.1089/jpm.2020.0800Test
Journal of Palliative Medicine, 24(12), 1789-1797. Mary Ann Liebert Inc.
Journal of Palliative Medicine, 24, 12, pp. 1789-1797
Journal of Palliative Medicine, 24, 1789-1797

مصطلحات موضوعية: Male, medicine.medical_specialty, Medical Overuse, Castration resistant, Prostate cancer, SDG 3 - Good Health and Well-being, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Medicine, Registries, General Nursing, Netherlands, Retrospective Studies, Terminal Care, business.industry, High intensity, General Medicine, medicine.disease, Prostatic Neoplasms, Castration-Resistant, Anesthesiology and Pain Medicine, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Emergency medicine, Hospital admission, business, End-of-life care, Life phase

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4add06b482c8b42c6f4158cc5bdf89Test
https://research.vumc.nl/en/publications/13bcb35e-f6d1-4c15-a1e8-8d67db323f51Test

المؤلفون: Katja K.H. Aben, Carin A. Uyl-de Groot, Joan van den Bosch, Inge M. van Oort, Saskia van der Meer, Andries M. Bergman, Jules L.L.M. Coenen, Winald R. Gerritsen, Diederik M. Somford, Hans M. Westgeest, Jules Lavalaye, Alphons C.M. van den Bergh, Mathijs P. Hendriks, Maarten J. van der Doelen, Malou C.P. Kuppen, Filiz Celik, Marco B. Polee, Alphonsus J. M. van den Eertwegh

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, Health Technology Assessment (HTA), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: Kuppen, M C, Westgeest, H M, van der Doelen, M J, van den Eertwegh, A J, Coenen, J L, Aben, K K, van den Bergh, A C, Bergman, A M, den Bosch, J V, Celik, F, Hendriks, M P, Lavalaye, J, der Meer, S V, Polee, M B, Somford, D M, van Oort, I M, Uyl-de Groot, C A & Gerritsen, W R 2020, ' Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer ', Future Oncology, vol. 16, no. 19, pp. 1371-1384 . https://doi.org/10.2217/fon-2020-0039Test
Future Oncology, 16(19), 1371-1384. Future Medicine Ltd.
Future Oncology, 16, 19, pp. 1371-1384
Future oncology, 16(19), 1371-1384. FUTURE MEDICINE LTD
Future Oncology, 16, 1371-1384

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Treatment completion, Databases, Factual, radium-223, THERAPY, RECOMMENDATIONS, Prostate cancer, DOUBLE-BLIND, 0302 clinical medicine, Aged, 80 and over, BONE METASTASES, Real world outcomes, CYCLES, General Medicine, sequencing, Middle Aged, real-world outcomes, Survival Rate, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, TRIAL, medicine.drug, Radium, Radium-223, medicine.medical_specialty, PHASE-3, Antineoplastic Agents, Bone Neoplasms, Castration resistant, survival, Drug Administration Schedule, Double blind, EVENTS, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Humans, Radium-223 Dichloride, Aged, Retrospective Studies, Radioisotopes, Window of opportunity, business.industry, medicine.disease, EFFICACY, skeletal-related events, 030104 developmental biology, metastatic castration-resistant prostate cancer, EXPERIENCE, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b016678894ad456a0d9a4e1e94d887b8Test
https://pure.eur.nl/en/publications/f28d6113-b2c9-48d2-b4bf-904818fb828dTest

المؤلفون: Haiko J. Bloemendal, Niven Mehra, Marco B. Polee, Joan van den Bosch, Alphonsus J. M. van den Eertwegh, Carin A. Uyl-de Groot, Daan ten Bokkel Huinink, H. P. (Pieter) van den Berg, Andre M. Bergman, Inge M. van Oort, Malou C.P. Kuppen, Addy C. M. van de Luijtgaarden, Laurent M.C.L. Fossion, Mathijs P. Hendriks, Juleon L.L.M. Coenen, Winald R. Gerritsen, Hans M. Westgeest, A.C.M. van den Bergh, Ronald de Wit, N.I. Weijl

المساهمون: Health Technology Assessment (HTA), Medical Oncology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical oncology, CCA - Cancer Treatment and quality of life

المصدر: Clinical Genitourinary Cancer, 17, 5, pp. e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018Test
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956

مصطلحات موضوعية: Male, Oncology, medicine.medical_treatment, 030232 urology & nephrology, PLUS PREDNISONE, Androgen deprivation therapy, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Neoplasm Metastasis, Netherlands, DOCETAXEL, Clinical Trials as Topic, education.field_of_study, CYCLES, Abiraterone acetate, Standard of Care, MEN, Middle Aged, CHEMOTHERAPY, Prognosis, OPEN-LABEL, ABIRATERONE ACETATE, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Docetaxel, Cabazitaxel, SAFETY, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, POSTDOCETAXEL, Taxoids, medicine.drug, Registry, medicine.medical_specialty, Urology, Population, INCREASED SURVIVAL, Antineoplastic Agents, 03 medical and health sciences, Trial eligibility, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Real-world outcomes, education, Aged, Retrospective Studies, Chemotherapy, L-Lactate Dehydrogenase, business.industry, Prostate-Specific Antigen, medicine.disease, Survival Analysis, Trial population, Clinical trial, chemistry, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55db3d2d7c2abd92a4b76a9b4278c5eTest
https://doi.org/10.1016/j.clgc.2019.05.018Test

المؤلفون: Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Health Technology Assessment (HTA), Medical oncology, Urology, CCA - Cancer Treatment and quality of life, Internal medicine

المصدر: European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005Test
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV

مصطلحات موضوعية: Oncology, Male, ANTITUMOR-ACTIVITY, 030232 urology & nephrology, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Prednisone, Medicine, Sequencing, Registries, Castration-resistant prostate cancer, DOCETAXEL, Abiraterone acetate, TIME, Prostatic Neoplasms, Castration-Resistant, TRIALS, Docetaxel, Pharmaceutical Preparations, Cabazitaxel, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Androgens, Cross resistance, medicine.drug, medicine.medical_specialty, CLINICAL-OUTCOMES, ENZALUTAMIDE, Urology, INCREASED SURVIVAL, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Antigen, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Enzalutamide, Humans, Radiology, Nuclear Medicine and imaging, Real-world outcomes, Retrospective Studies, Androgen-receptor targeting agents, business.industry, Androgen Antagonists, medicine.disease, Androgen receptor, chemistry, Surgery, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810Test
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028Test

المؤلفون: Alphons C.M. van den Bergh, Hans M. Westgeest, Walter L. Vervenne, Niven Mehra, Diederik M. Somford, Jules L.L.M. Coenen, Inge M. van Oort, Alfons J.M. van den Eertwegh, Malou C.P. Kuppen, Reindert J.A. van Moorselaar, Jessica Notohardjo, Carin A. Uyl-de Groot, Winald R. Gerritsen, Aad I. de Vos, Katja K.H. Aben, Andries M. Bergman

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Health Technology Assessment (HTA), Medical oncology, Urology, CCA - Cancer Treatment and quality of life

المصدر: European Urology Focus, 7, 4, pp. 788-796
European Urology Focus, 7(4), 788-796. De Tijdstroom/Elsevier
Notohardjo, J C L, Kuppen, M C P, Westgeest, H M, van Moorselaar, R J A, Mehra, N, Coenen, J L L M, van Oort, I M, de Vos, A I, Vervenne, W L, van den Bergh, A C M, Aben, K K H, Somford, D M, Bergman, A M, Uyl-de Groot, C A, Gerritsen, W R & van den Eertwegh, A J M 2021, ' Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Focus, vol. 7, no. 4, pp. 788-796 . https://doi.org/10.1016/j.euf.2020.03.009Test
European Urology Focus. Elsevier
European Urology Focus, 7, 788-796
European Urology Focus, 7(4), 788-796. Elsevier BV

مصطلحات موضوعية: Male, Oncology, PREDNISONE, medicine.medical_specialty, ENZALUTAMIDE, Urology, ANTITUMOR-ACTIVITY, Population, 030232 urology & nephrology, Life-prolonging drug, Castration resistant, 03 medical and health sciences, Drug treatment, Prostate cancer, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Internal medicine, hemic and lymphatic diseases, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Humans, Real-world outcomes, Prospective Studies, Registries, education, Retrospective Studies, Castration-resistant prostate cancer, DOCETAXEL, education.field_of_study, business.industry, Real world outcomes, Third line, CHEMOTHERAPY, Prognosis, medicine.disease, PROGNOSTIC MODEL, MITOXANTRONE, Clinical Practice, ABIRATERONE ACETATE, Prostatic Neoplasms, Castration-Resistant, 030220 oncology & carcinogenesis, CABAZITAXEL, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Prognostic model, SURVIVAL, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::863af5bcaa0e4492253e7fa5bfd10a57Test
https://repository.ubn.ru.nl/handle/2066/237201Test

المؤلفون: Paul J.M. Kil, Carin A. Uyl-de Groot, Johanna J.M. Takkenberg, Hans M. Westgeest, Kevin M Veen, M. Mostafa Mokhles, Isabel B. de Angst, Winald R. Gerritsen, Malou C.P. Kuppen

المساهمون: Cardiothoracic Surgery, Health Technology Assessment (HTA)

المصدر: Journal of Cancer Research and Clinical Oncology, 146, 2067-2075. Springer-Verlag
Journal of Cancer Research and Clinical Oncology, 146, 2067-2075
Journal of Cancer Research and Clinical Oncology, 146, 8, pp. 2067-2075
Journal of Cancer Research and Clinical Oncology

مصطلحات موضوعية: Male, Cancer Research, Review – Clinical Oncology, Computer science, Clinical Decision-Making, Machine learning, computer.software_genre, 01 natural sciences, 010104 statistics & probability, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Lasso (statistics), SDG 3 - Good Health and Well-being, medicine, Humans, 030212 general & internal medicine, Registries, 0101 mathematics, Castration-resistant prostate cancer, Netherlands, Proportional Hazards Models, Retrospective Studies, Models, Statistical, Proportional hazards model, business.industry, General Medicine, Missing data, medicine.disease, Decision Support Systems, Clinical, Regression, Prostatic Neoplasms, Castration-Resistant, Specification, Oncology, Prediction modeling, Cox proportional hazard model, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Regression Analysis, Artificial intelligence, business, computer, Statistician, Coding (social sciences), Decision-making

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3417c1289a73f67b18a369cc28e6a76eTest
https://pure.eur.nl/en/publications/d9c008f1-f498-4ef5-94d3-42786d5f1a55Test

المؤلفون: Samhita Pamidimarri Naga, Inge M. van Oort, Marleen L Duizer, Winald R. Gerritsen, Leonie I. Kroeze, Haiko J. Bloemendal, Malou C.P. Kuppen, Niven Mehra, Jack A. Schalken, Marjolijn J. L. Ligtenberg, Carin A. Uyl-de Groot, Hans M. Westgeest, Iris S.H. Kloots, Peter H.J. Slootbeek, Maarten J. van der Doelen

المساهمون: Health Technology Assessment (HTA)

المصدر: International Journal of Cancer, 148(2), 385-395. Wiley-Liss Inc.
International Journal of Cancer, 148, 385-395
International Journal of Cancer, 148, 2, pp. 385-395
International Journal of Cancer

مصطلحات موضوعية: Male, Oncology, Cancer Research, DNA Repair, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], medicine.medical_treatment, homologous recombination, Kaplan-Meier Estimate, Carboplatin, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, aggressive variant prostate cancer, Antineoplastic Combined Chemotherapy Protocols, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Netherlands, metastatic castration‐resistant prostate cancer, DNA Damage Repair, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, Cohort, Taxoids, medicine.medical_specialty, DNA repair, Poly(ADP-ribose) Polymerase Inhibitors, Castration resistant, Cancer Genetics and Epigenetics, 03 medical and health sciences, Antigen, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Humans, Germ-Line Mutation, Aged, Neoplasm Staging, Retrospective Studies, BRCA2 Protein, Chemotherapy, business.industry, medicine.disease, chemistry, Drug Resistance, Neoplasm, business, DNA Damage

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79c4ae93d35fe9784f95113f76a3af3Test
https://pure.eur.nl/en/publications/73fcb740-8fb5-4724-a40b-bf1b43f68133Test

المؤلفون: Malou C.P. Kuppen, Niven Mehra, Maarten J. van der Doelen, Marcel J.R. Janssen, Marianne A. Jonker, Inge M. van Oort, Winald R. Gerritsen

المصدر: Clinical Nuclear Medicine, 43, 1, pp. 9-16
Clinical Nuclear Medicine, 43, 9-16

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, MEDLINE, Bone Neoplasms, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Castration resistant, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Prostate cancer, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Daily practice, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Overall survival, Humans, Radiology, Nuclear Medicine and imaging, In patient, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Proportional hazards model, business.industry, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Prostatic Neoplasms, Castration-Resistant, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, business, Radium

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e93594dfcb645d9162cf545e7db8015bTest
https://doi.org/10.1097/rlu.0000000000001904Test

المؤلفون: Niven Mehra, Jules Lavalaye, W R Gerritsen, Malou C.P. Kuppen, H.M. Westgeest, J. Van Moorselaar, D.M. Somford, F. Van Den Eertwegh, F. Van Den Bergh, Andre M. Bergman, Katja K.H. Aben, Jules L.L.M. Coenen, C.A. Uyl-de Groot

المصدر: European Urology Supplements. 17:e2891-e2893

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Urology, Anti-Androgen, Castration resistant, medicine.disease, chemistry.chemical_compound, Prostate cancer, chemistry, Internal medicine, Medicine, Enzalutamide, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2d121ee6d702e44bf827f95033cf8e78Test
https://doi.org/10.1016/s1569-9056Test(18)33756-4